PT  - JOURNAL ARTICLE
AU  - SUDHA VISVANATHAN
AU  - CARRIE WAGNER
AU  - JEANNIE ROJAS
AU  - JONATHAN KAY
AU  - BHASKAR DASGUPTA
AU  - ERIC L. MATTESON
AU  - MICHAEL MACK
AU  - DANIEL G. BAKER
AU  - MAHBOOB U. RAHMAN
TI  - E-selectin, Interleukin 18, Serum Amyloid A, and Matrix Metalloproteinase 9 Are Associated with Clinical Response to Golimumab plus Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
AID  - 10.3899/jrheum.080755
DP  - 2009 Jul 01
TA  - The Journal of Rheumatology
PG  - 1371--1379
VI  - 36
IP  - 7
4099  - http://www.jrheum.org/content/36/7/1371.short
4100  - http://www.jrheum.org/content/36/7/1371.full
SO  - J Rheumatol2009 Jul 01; 36
AB  - Objective. To assess the effect of golimumab (human monoclonal antibody to tumor necrosis factor-α) plus methotrexate (MTX) on selected inflammatory biomarkers, and to determine if these effects predict clinical response in rheumatoid arthritis (RA). Methods. Sera from adults with active RA despite MTX therapy, who received subcutaneous injections of placebo + MTX (MTX alone, n = 34) or golimumab 50 or 100 mg every 2 or 4 weeks + MTX (n = 137), were analyzed for levels of C-reactive protein (CRP), serum amyloid A (SAA), interleukin 18 (IL-18), E-selectin, matrix metalloproteinase 9 (MMP-9), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). Results. Golimumab + MTX treatment significantly decreased serum CRP, SAA, IL-18, E-selectin, TIMP-1, and MMP-9 levels (median percent changes of −4.1% to −74.3% across treatment groups) versus MTX alone (−5.8% to 9.7%) when first measured at Week 4; decreases were sustained through Week 16. Larger magnitudes of decrease in all biomarkers were observed for clinical responders versus nonresponders. For golimumab + MTX, regression analyses including all biomarkers and select clinical measures showed that reductions in levels of several markers (SAA, E-selectin, MMP-9) as early as Week 4 correlated significantly with improvement in swollen joint count (SJC) at Week 16, as did reductions in E-selectin with improvement in tender joint count at Week 16. After accounting for the biomarkers, however, treatment group was no longer significant for SJC. Conclusion. Significant decreases in several inflammatory biomarkers were associated with golimumab + MTX therapy. Decreases in serum levels of SAA, E-selectin, and MMP-9 at Week 4 may be useful in predicting clinical response at Week 16.